Abstract Library

#4635 Comparison of 18F-DOPA PET/CT and 68Ga-DOTATOC PET/CT and their impact on response to PRRT in midgut neuroendocrine tumours

Introduction: 18F-DOPA PET/CT is a powerful diagnostic test for assessing tumour burden in midgut neuroendocrine tumours (NETs). 68Ga-DOTATOC PET/CT is required for patient selection for PRRT.

Conference:

Presenting Author: Longo M

Authors: Longo M, Coccarelli A, Henry T, Kamoun T, Morbelli S,

Keywords: F-DOPA, Ga-DOTATOC, PRRT, midgut,

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4612 Intraoperative beta-probe for pathological tissue detection in GEP-NET patients: A prospective phase II trial

Introduction: Accurate localisation of gastroenteropancreatic neuroendocrine tumours (GEP-NET) is essential for successful radical surgery. Radio guided surgery (RGS) is an innovative technique that may enhance lesion detection.

Conference:

Presenting Author: Bertani E

Authors: Bertani E, Fumagalli Romario U, Collamati F, Ferrari M, Mattana F,

Keywords: radio guided surgery, surgery, neuroendocrine tumour, GEP-NET, gastrointestinal tumour,

#4370 Role of 68GA-DOTATOC pet/ct in therapeutic decision-making for well-differentiated neuroendocrine tumours

Introduction: 68Ga-DOTATOC PET/CT is a highly sensitive and specific test for assessing gastroenteropancreatic and pulmonary neuroendocrine tumours (NET) expressing somatostatin receptors.

Conference:

Presenting Author: Cruz-Diaz W

Authors: Cruz Diaz W, Landaeta Kancev L, Martinez-Amores Martínez B, Bastidas Tamayo J, Estrella Santos A,

Keywords: 68Ga-DOTATOC PET/CT, well-differentiated, gastroenteropancreatic, pulmonary, neuroendocrine tumour, Lu-177-DOTATATE,

#4115 Neoadjuvant PRRT with 90Y-DOTATOC: Preliminary results from a monocentric perspective study

Introduction: Surgery is considered the only curative treatment for pancreatic neuroendocrine tumors (pNETs), but it is feasible only in a few patients. A new possible strategy in pNETs is preoperative PRRT, as its cytoreductive effect could increase the efficacy of surgery.

Conference:

Presenting Author:

Authors: Barone A, Grana C, Papi S, Bertani E, Rocca P,

Keywords: PRRT, 90Y-DOTATOC, Neoadjuvant PRRT, pancreatic NET,